Clinical study in rural Uganda shows high demand for antiretroviral drugs

July 22, 2012

An ongoing clinical study in rural Uganda, begun in 2011, suggests that many people infected with HIV/AIDS would take antiretroviral drugs if they were available to them—even before they developed symptoms from the disease.

Led by doctors at the University of California, San Francisco (UCSF), the San Francisco General Hospital and Trauma Center (SFGH) and Makerere University School of Medicine in Kampala, , the study is the first to address such attitudes among African who are in the early stages of the disease and not yet sick.

Historically, treatment was initiated only when someone's immune system had declined below a certain threshold, by which point they were sometimes already ill.

Now, mounting evidence suggests that providing antiretroviral to people long before they get sick can be a direct benefit to both them and society—by keeping the individual healthy, and by reducing the transmission of within communities.

Even so, scientists have known little about patients' attitudes towards taking antiretroviral therapy in the early stages of HIV disease. "Given that there are millions of people in Africa taking and millions more in need of them, there is surprisingly little data on patients' attitudes in this part of the world toward the therapy itself," said Moses Kamya, a professor and chair of the Department of Medicine at Makerere University.

The new clinical study addressed these questions directly. Its first results will be revealed at the XIX International Conference in Washington, D.C. on Sunday, July 22, 2012.

"There was very high interest among the people eligible for this study in taking antiretrovirals," said Vivek Jain, MD, MAS, assistant professor of medicine in the UCSF Division of HIV/AIDS at SFGH.

In the study, 188 patients with HIV were enrolled and offered antiretroviral drugs. All had a high CD4+ T cell count (>350)—the classic measure of the immune system's robustness and an indication of being in the early stages of disease, before a decline towards AIDS.

Almost all of the patients—186 of 188—elected to take the treatment. Ninety percent identified the main reason why they wanted to start therapy as their desire to stay healthy, 52 percent cited a desire to continue working and an equal 52 percent cited a desire to continue caring for their families. Other leading reasons patients wanted to take therapy centered around their desire not to transmit HIV to partners and future children.

The poster, "Patient attitudes toward HIV antiretroviral therapy initiation at high CD4+ cell counts" by Vivek Jain, Dathan Byonanebye, Jemimah Muhaawe, Jane Kabami, Doug Black, Tamara Clark, Gabriel Chamie, Elvin Geng, James Rooney, Edwin Charlebois, Gideon Amanyire, Diane Havlir, Moses Kamya, and the SEARCH Collaboration will be unveiled at 3:00 p.m. ET on Sunday, July 22, 2012.

Explore further: HIV rate in SF could be cut sharply with expanded treatment, study predicts

More information: pag.aids2012.org/abstracts.aspx?aid=5458

Related Stories

HIV rate in SF could be cut sharply with expanded treatment, study predicts

April 13, 2011
If HIV-infected adults in San Francisco began taking antiretroviral treatments as soon as they were diagnosed, the rate of new HIV infections among men who have sex with men would be cut by almost 6o percent over five years, ...

New study adds further guidance on when to start antiretroviral therapy for HIV

September 26, 2011
One of the key decisions faced by people living with HIV, and by their health-care providers, is when to start treatment.

Only one-third of HIV-positive patients remain in care before starting treatment

July 19, 2011
In sub-Saharan Africa, only about one third of patients who test positive for HIV but are not yet eligible for antiretroviral treatment remain in care until they become eligible and start treatment. Some patients never return ...

Blood cell test for HIV treatment monitoring is cheaper but just as effective

December 1, 2011
(Medical Xpress) -- A cheaper laboratory test that helps guide anti-retroviral drug treatment for people with HIV/AIDS may be just as effective as a more sophisticated test, a group of international researchers has found ...

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.